Biotech (General) Archives - Page 6 of 15

DECENTRALIZED TRIALS & RESEARCH ALLIANCE (DTRA) LAUNCHES TO DEMOCRATIZE AND ACCELERATE CLINICAL TRIALS

Dec 11, 2020Biotech (General), Clinical Trials

December 10, 2020 – An historic alliance of life sciences and healthcare organizations seeks to accelerate the broad adoption of patient-focused, decentralized clinical trials and research. The Decentralized Trials & Research Alliance (DTRA) plans to unite stakeholders, including healthcare companies, regulators, patient groups and research organizations, with a mission to make clinical trial participation widely accessible […]

Report Study | Impact of COVID-19 on the Global Rare Neurodegenerative Disease Treatment Market

Dec 2, 2020Biotech (General), Neurodegenerative Disorders

A new study on the Rare Neurodegenerative Disease Treatment market provides a detailed overview of the demands and consumptions of various products/services associated with the growth dynamics of the market. The in-depth market estimation of various opportunities in the segments is expressed in volumes and revenues during the forecast period 2020 to 2030. The insights and […]

Bay Area woman lobbying for passage of ALS bill

Nov 9, 2020ALS, Biotech (General), Clinical Trials

When Jamie Berry noticed a slight limp in her right foot in late May, she didn’t think much of it. Berry tends horses and drives tractors on the 80-acre ranch her family leases in San Jose’s Almaden Valley, and she was also busy with an 8-year-old daughter, five dogs and an excavation business she runs […]

Is Sorrento Therapeutics Stock a Buy?

Oct 25, 2020Biotech (General), Biotech Stocks To Watch, COVID-19

Back in May, Sorrento Therapeutics (NASDAQ:SRNE) captivated investor attention after it claimed the discovery of an antibody that can provide “100% inhibition” against COVID-19. In fact, the company’s senior vice president, Dr. Mark Brunswick, made the following statement in an interview by Fox News: “So, if we were approved [by the U.S. Food and Drug […]

REGENERON’S ANTIBODY COCKTAIL REGN-EB3 (INMAZEB®) IS FIRST FDA-APPROVED TREATMENT FOR EBOLA (ZAIRE EBOLAVIRUS)

Oct 25, 2020Biotech (General), Biotech Stocks To Watch, Corporate News

In a large clinical trial, Inmazeb showed superiority compared to other investigational agents (ZMapp and remdesivir) with respect to mortality; treatment was most effective when given early in the course of disease1 Inmazeb (atoltivimab, maftivimab and odesivimab-ebgn) is a novel anti-viral antibody medicine developed using the same ‘rapid response’ technologies as Regeneron’s investigational COVID-19 antibody […]

Bausch Health And BHVI Announce Exclusive Global Licensing Agreement For Myopia Control Contact Lens

Oct 17, 2020Biotech (General), Corporate News

Second Exclusive License Strengthens Bausch + Lomb’s Global Research Focus on Myopia SYDNEY and LAVAL, QC, Oct. 15, 2020 /PRNewswire/ — Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”) and Bausch + Lomb, its leading global eye health business, along with BHVI, an Australian not-for-profit organization with an international focus on vision research, announced today that an […]

Japan Grants Patent to Brainstorm Covering Technique for NurOwn

Sep 25, 2020ALS, Biotech (General), Biotech Stocks To Watch, Clinical Trials, Corporate News, Multiple Sclerosis

The Japan Patent Office has granted a patent to Brainstorm Cell Therapeutics covering the proprietary technique that generates the company’s cell-based therapy NurOwn from mesenchymal stem cells (MSCs). Through this technique, researchers can harness MSCs directly from a patient and mature them into cells that produce high levels of neurotrophic factors, which are compounds that […]

Fierce Innovation Awards — Life Sciences Edition 2020: Winners Announcement!

Sep 14, 2020Biotech (General)

The Fierce Innovation Awards: Life Sciences Edition have come to a close and we’re pleased to announce the 2020 award winners! These awards are designed to showcase organizations that over the past 12 months have demonstrated innovative technologies and services that have the potential to make the greatest impact for biotech and pharma companies. With […]

Novartis presents data at ACTRIMS-ECTRIMS for Kesimpta® (ofatumumab) in newly diagnosed treatment-naïve adults with relapsing multiple sclerosis

Sep 13, 2020Biotech (General), Clinical Trials, Multiple Sclerosis

New post hoc data from Phase III ASCLEPIOS trials showed newly diagnosed, treatment-naïve patients experienced reductions in annualized relapse rates, MRI lesion activity and reductions in time to disability worsening when treated with Kesimpta vs teriflunomide(1) Additional safety data in over 1,800 patients who continued Kesimpta treatment or switched therapy from previous studies reinforce the […]

Trump Administration’s Operation Warp Speed Accelerates AstraZeneca COVID-19 Vaccine to be Available Beginning in October

Aug 24, 2020Biotech (General), Clinical Trials, COVID-19

Responding to President Trump’s call to develop 300 million doses of SARS-CoV-2 vaccine by January under Operation Warp Speed, the U.S. Department of Health and Human Services (HHS) and AstraZeneca are collaborating to make available at least 300 million doses of a coronavirus vaccine called AZD1222, with the first doses delivered as early as October […]